Safety of elobixibat and lubiprostone in Japanese patients with chronic constipation: a retrospective cohort study

CONCLUSION: No new safety concerns have been raised in relation to elobixibat and lubiprostone use for treating chronic constipation, although the HR of different events varied. Further larger-scale study is needed as the estimates for events of small numbers were unstable.PMID:34281471 | DOI:10.1080/14740338.2021.1952980

Source: Expert Opinion on Drug Safety - July 20, 2021 Category: Drugs & Pharmacology Authors: Nobuhiro Ooba Yoshinori Takahashi Marina Nagamura Masao Takahashi Makoto Ushida Eiji Kawakami Masaomi Kimura Tsugumichi Sato Junichi Tokuyoshi Choichiro Miyazaki Mitsuaki Shimada Source Type: research